Why this promising small-cap ASX stock could rise almost 80%

MotleyFool

03/24

Amplia Therapeutics Ltd (ASX: ATX) shares certainly had a day to remember on Monday. When many ASX shares were tumbling with the market, this small-cap stock doubled in value to 23.5 cents. The ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2621087206"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621087206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621087206?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 05:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621087206","market":"us","top_or_hot":-1,"title":"Why this promising small-cap ASX stock could rise almost 80%","media":"MotleyFool","content":"<div>\n<p>Amplia Therapeutics Ltd (ASX: ATX) shares certainly had a day to remember on Monday. When many ASX shares were tumbling with the market, this small-cap stock doubled in value to 23.5 cents. The ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/24/why-this-promising-small-cap-asx-stock-could-rise-almost-80/\">网页链接</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why this promising small-cap ASX stock could rise almost 80%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy this promising small-cap ASX stock could rise almost 80%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 05:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2026/03/24/why-this-promising-small-cap-asx-stock-could-rise-almost-80/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amplia Therapeutics Ltd (ASX: ATX) shares certainly had a day to remember on Monday. When many ASX shares were tumbling with the market, this small-cap stock doubled in value to 23.5 cents. The ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/24/why-this-promising-small-cap-asx-stock-could-rise-almost-80/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.fool.com.au/2026/03/24/why-this-promising-small-cap-asx-stock-could-rise-almost-80/","article_id":"2621087206","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/24/why-this-promising-small-cap-asx-stock-could-rise-almost-80/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621087206","pubTimestamp":1774302152,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Amplia Therapeutics Ltd  shares certainly had a day to remember on Monday. When many ASX shares were tumbling with the market, this small-cap stock doubled in value to 23.5 cents. The catalyst for this was the release of updated data from the single-arm Phase 1b/2 ACCENT trial evaluating narmafotinib plus chemotherapy in 64 metastatic pancreatic cancer patients. Image source: Getty Images Is it too late to buy this small-cap ASX stock?","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","ATX.AU":"AMPLIA THERAPEUTICS LTD"},"translate_title":"为什么这只前景光明的澳大利亚证券交易所小盘股可以上涨近80%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATX.AU":1},"content_text":"Amplia Therapeutics Ltd (ASX: ATX) shares certainly had a day to remember on Monday. When many ASX shares were tumbling with the market, this small-cap stock doubled in value to 23.5 cents. The catalyst for this was the release of updated data from the single-arm Phase 1b/2 ACCENT trial evaluating narmafotinib plus chemotherapy in 64 metastatic pancreatic cancer patients. Image source: Getty Images Is it too late to buy this small-cap ASX stock? Despite its incredible rise on Monday, Bell Potter believes there is still potential for the pharmaceutical company's shares to rise materially from current levels. In response to yesterday's big announcement from Amplia Therapeutics, the broker said: The new data was from pre-planned analysis by independent central reviewers, as opposed to analysis by the site investigators which had been reported up until today. The clear highlight was the classification of four new confirmed complete responders. This takes the total to five confirmed complete responders deemed to have disappearance of all measurable lesions for at least two months. The five confirmed complete responders – i.e. 8% of treated patients (n=5/64) – is a remarkable outcome when comparing to the three historical Phase 3 trials with the same chemo backbone where complete responses were seen in only 1 in ~500 subjects (well below 1%). Additionally, when comparing to other novel drugs in active development, none we are tracking have reported more than 1-2 complete responders. While caveats related to single-arm, mid-size studies remain relevant, the outcomes reported today provide further compelling evidence that narmafotinib's anti-fibrotic mechanism is allowing chemo to exert greater effect and penetrate tumour tissue more effectively. Big potential returns remain According to the note, the broker has retained its speculative buy rating and 42 cents price target on the small-cap ASX stock. Based on its current share price, this implies potential upside of almost 80% for investors over the next 12 months. However, given its speculative nature, this would only be suitable for investors with a high tolerance for risk. Commenting on the small-cap ASX stock, the broker said: No material changes to our forecasts or valuation following this update. We maintain our BUY (speculative) recommendation. Upcoming catalysts include (1) early updates from the AMPLICITY Phase 1b study in 2H CY26; (2) announcements related to any new clinical studies in combination with kRas inhibitors or in ovarian cancer patients, albeit timing is speculative; and (3) updates on the Phase 2b/3 trial preparations.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}